MI - Use of Beta Blocker Therapy
Description
The percentage of patients aged 18 years and older diagnosed with myocardial infarction (MI) who are taking a beta blocker
The percentage of patients aged 18 years and older diagnosed with myocardial infarction (MI) who are taking a beta blocker
This measure identifies patients with new-onset atrial fibrillation during the measurement year who have had a thyroid function test 6 weeks before or after the diagnosis of atrial fibrillation.
The percentage of patients aged 18 years and older with proteinuria who are taking an angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)
Percentage of patients transferred to another HEALTHCARE FACILITY whose medical record documentation indicated that nursing information was communicated to the receiving FACILITY within 60 minutes of departure
The percentage of women aged 55 years and older, or men, aged 50 years and older, who are taking chronic steroids (>/=3 months), and are taking drugs to prevent osteoporosis
The percentage of women, aged 55 and older, or men, aged 50 and older, with a diagnosis of osteoporosis who are taking osteoporosis therapy.
The percentage of women age 50-85 who suffered a fracture and who either had a bone mineral density test or received a prescription for a drug to treat osteoporosis.
Percentage of patients, regardless of age, with a current diagnosis of Stage 0 through IIC melanoma or a history of melanoma of any stage, without signs or symptoms suggesting systemic spread, seen for an office visit during the one-year measurement period, for whom no diagnostic imaging studies were ordered
Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who started antiviral treatment within the 12 month reporting period for whom quantitative hepatitis C virus (HCV) ribonucleic acid (RNA) testing was performed within 12 months prior to initiation of antiviral treatment
Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who started antiviral treatment within the 12 month reporting period for whom hepatitis C virus (HCV) genotype testing was performed within 12 months prior to initiation of antiviral treatment